Brenus Pharma Joins the Paris Saclay Cancer Cluster (PSCC) to Collaborate at the Heart of Innovation in Oncology

Contributed by: Business Wire

Logo

Tags

Other Health

Research

Pharmaceutical

Oncology

Biometrics

Other Education

Education

Clinical Trials

Science

Biotechnology

Other Science

Health

Paris Saclay Cancer Cluster

More Like This

Brenus Pharma, Winner of the Call for Proposals "Innovations in Biotherapies and Bioproduction for France 2030", Receives €5 Million for Its Anticancer Vaccine Immunotherapy

Brenus Pharma graduates from the Creative Destruction Lab’s 2023/2024 Global Cancer Stream, in partnership with North American Universities.

Biotech Award presented to Paul Bravetti (CEO Brenus Pharma) by Thierry Hulot (President of Merck Group activities in France - President of LEEM), Alain Huriez (Chariman and Managing Partner, AdBio Partners), Guillaume LAULHE (Director BD at IQVIA) (Photo: Brenus Pharma)

Brenus Pharma Wins the "Biotech" Trophy at the Prestigious Healthtech 2024 Awards Ceremony, Organized by France Biotech

Brenus Pharma Wins French Tech Saint-Etienne Lyon's BIG Start-up of the Year Award

AACR 2024: Brenus Pharma Unveils Promising and Robust Pre-clinical Efficacy Extrapolating Human Conditions with STC-1010

Brenus Pharma Publishes Promising Proof of Concept Results of their Therapeutic Platform in the Scientific Frontiers in Oncology Journal. (1)

ASCO 2024: Brenus Pharma Presented “BreAK-CRC” First-in-human (FIH) Phase I/IIA Trial of STC-1010: a Next-generation Cancer Vaccine Targeting mCRC

PR Newswire associated0

Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology